Intervention effects and safety of cardiovascular polypill for the relevant risk factors of coronary heart disease: A systematic review

Chinese Journal of Evidence-Based Medicine

Volumn 13, Issue 4, 2013, Pages 446-451

  Xing, Dong Mei ^a   Zhang, Jun Hua ^a   Li, Ling ^a   Zhu, Ming Jun ^b   Shang, Hong Cai ^a  

^a TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b HENAN UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Coronary heart disease; Polypill; Randomized controlled trial; Systematic review

Indexed keywords

CARDIOVASCULAR AGENT; CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLYPILL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ARTICLE; BLEEDING; BLOOD PRESSURE; COUGHING; DRUG SAFETY; GASTRITIS; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LIVER FAILURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SYSTEMATIC REVIEW;

EID: 84930650042     PISSN: 16722531     EISSN: None     Source Type: Journal    
DOI: 10.7507/1672-2531.20130077     Document Type: Article

References (22)

1. World Health Organization. The global burden of disease: 2004 update. Geneva: World Health Organization. 2008.
2. Murray CJL, Lauer JA, Hutubessy RCW, et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovasculardisease risk. Lancet, 2003, 361(9359): 717-725.
3. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ, 2003, 326(7404): 1419-1424.
4. Yusuf S. Two decades of progress in preventing vascular disease. Lancet, 2002, 360(9326): 2-3.
5. New Zealand Guidelines Group. Evidence-based best practice guideline. The assessment and management of cardiovascular risk. 2003.
6. Heeley EL, Peiris DP, Patel AA, et al. Cardiovascular risk perception and evidence-practice gaps in Australian general practice (the Aus HEART study). Med J, 2010, 192(5): 254-259.
7. Burkhart PV, Sabate E. Adherence to long-term therapies: evidence for action. J Nurs Scholarsh, 2003, 35(3): 207.
8. Wald NJ, Law MR. Formulation for the Prevention of Cardiovascular Disease. UK Patents GB008791 and GB0100548. 2000.
9. Frishman WH, Zuckerman AL. Amlodipine / atorvastatin: the first cross risk factor for polypill for the prevention and treatment of cardiovascular disease. Expert Rev Cardiovasc Ther, 2004, 2(5): 675-681.
10. Clinical Trials Research Unit. The University of Auckland (online 2008) PILL Pilot: Programme to Improve Life and Longevity [http://www.ctru.auckland.ac.nz/content/view/37/35/]. (Last accessed 5th February 2009).
11. Xavier D, Pais P, Sigamani A, et al. The need to test the theories behind the Polypill: rationale behind the Indian Poly-cap Study. Nat Clin Pract Cardiovasc Med, 2009, 6(2): 96-97.
12. Higgins JTP, Green S. Cochrane handbook for systematic reviews of interventions. Wiley Online Library, 2008.
13. The Indian Polycap Study (TIPS). Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomized trial. Lancet, 2009, 373(9672): 134-151.
14. Malekzadeh F, Marshall T, Pourshams A, et al. A pilot double-blind randomized placebo-controlled trial of the effects of fixed-dose combination therapy ("polypill") on cardiovascular risk factors. Int J Clin Pract, 2010, 64(9): 1220-1227.
15. PILL Collaborative Group. An international randomized placebocontrolled trial of a four-component combination pill ("Polypill") in people with raised cardiovascular risk. PloS One, 2011, 6(5): e19857.
16. Soliman ES, Mendis S, Dissanayake WP, et al. A Polypill for primary prevention of cardiovascular disease: A feasibility study of the World Health Organization. Trials, 2011,12: 3.
17. Wald DS, Morris JK, Wald NJ. Randomized polypill crossover trial in people aged 50 and over. PLoS One, 2012, 7(7): e41297.
18. Strong K, Mathers C, Leeder S, et al. Preventing chronic diseases: how many lives can we save? Lancet, 2005, 366(9496): 1578-1582.
19. Lim SS, Gaziano TA, Gakidou E, et al. Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs. Lancet, 2007, 370(9604): 2054-2062.
20. Zimmerli LU, Schiffer E, Zurbig P, et al. Urinary proteomics biomarkers in coronary artery disease. Mol Cell Proteomics, 2008, 7(2): 290-298.
21. Sanz G, Fuster V. Polypill and global cardiovascular health strategies. Semin Thorac Cardiovasc Surg, 2011, 23(1): 24-29.
22. Wise J. Polypill holds promise for people with chronic disease. Bull World Health Organ, 2005, 83(12): 885-887.